The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its future within the broader industry now triggers questions about long-term returns . Copycat versions are eroding market share, prompting worries that investing in companies heavily reliant to Viagra's once-dominant position could be a problematic